Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase
Journal of Medicinal Chemistry · 14.11.2024 · 67 (21) · 19736-19754
DOI: 10.1021/acs.jmedchem.4c02083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.10.2024. Verfasst von Jennifer X Qiao und 33 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Chemistry, Bristol Myers Squibb, Princeton, New Jersey 08540, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Protein Kinase Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
We describe the design, synthesis, and structure-activity relationship (SAR) of heterobifunctional RET ligand-directed degraders (LDDs) derived from three different second-generation RET inhibitors. These LDDs are composed of a target binding motif (TBM) that binds to the RET protein, a linker, and a cereblon binding motif (CBM) as the E3 ligase recognition unit. This led to the identification of a series of pyrazolopyridine-based heterobifunctional LDDs, as exemplified by compound 39. LDD 39 demonstrated high in vitro inhibitory and degradation potency against both RET wild-type and the two representative mutants, V804M and G810R. Importantly, in PK/PD studies, 39 exhibited a differentiated and favorable in vivo profile compared to the corresponding tyrosine kinase inhibitor (TKI), compound 3. Robust and sustained degradation of total-RET (tRET) protein and inhibition of phospho-RET (pRET) signaling were observed in TPC-1 xenograft tumors driven by RET and the RET/G810R mutant following a single dose of LDD 39 at 15 and 75 mg/kg, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Discovery Chemistry, Bristol Myers Squibb, Princeton, New Jersey 08540, United States.
- Molecular Structure & Design, Bristol Myers Squibb, Princeton, New Jersey 08540, United States.
- Oncology Discovery Biology, Mechanism of Cancer Resistance, Bristol Myers Squibb, Cambridge, Massachusetts 02141, United States.
- Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, New Jersey 08540, United States.
- Discovery Pharmacology and in vivo Biology, Bristol Myers Squibb, Cambridge, Massachusetts 02141, United States.
- Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Cambridge, Massachusetts 02141, United States.
ORCID-Profile: Jennifer X Qiao, Christopher Barbieri, Ashvinikumar V Gavai, T G Murali Dhar
Zitieren
APA
Qiao, J. X., Williams, D., Gill, P., Li, L., Norris, D., Tokarski, J. S., Wong, J., Qi, H., Hafeji, Y., Downes, D. P., Degnen, B., Wang, Y. K., Locke, G., Fang, H., Yu, F., Xu, S., Naglich, J., Zhang, J., Nanjappa, P., …, & Dhar, T. G. M. (2024). Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase. Journal of Medicinal Chemistry, 67(21), 19736-19754. https://doi.org/10.1021/acs.jmedchem.4c02083
Vancouver
Qiao JX, Williams D, Gill P, Li L, Norris D, Tokarski JS, et al. Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase. Journal of Medicinal Chemistry. 2024;67(21):19736-19754. doi:10.1021/acs.jmedchem.4c02083
BibTeX
@article{Qiao2024,
author = {Qiao, Jennifer X and Williams, David and Gill, Patrice and Li, Ling and Norris, Derek and Tokarski, John S and Wong, Jessica and Qi, Huilin and Hafeji, Yamnah and Downes, Daniel P and Degnen, Bill and Wang, Ying-Kai and Locke, Gregory and Fang, Hua and Yu, Fei and Xu, Songmei and Naglich, Joseph and Zhang, Jun and Nanjappa, Purushothama and Dai, Chao and Chourb, Lisa and Napoline, Jonathan and Tester, Richland and Jorge, Christine and Li, Yi-Xin and Mathur, Arvind and Barbieri, Christopher and Soars, Matthew G and Venkatanarayan, Avinashnarayan and Lees, Emma and Borzilleri, Robert M and Gavai, Ashvinikumar V and Wichroski, Michael and Dhar, T G Murali},
title = {Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {21},
pages = {19736--19754},
doi = {10.1021/acs.jmedchem.4c02083}
}
EUVIMED